论文部分内容阅读
目的分析吡格列酮对糖尿病胰岛素抵抗患者血糖、胰岛素敏感指数、C-反应蛋白(CRP)水平的影响,探讨其治疗2型糖尿病的临床疗效。方法将180例糖尿病胰岛素抵抗患者随机分为对照组和观察组两组,每组90例,对照组胰岛素治疗,观察组患者采用吡格列酮联合胰岛素治疗,比较治疗前后两组患者空腹血糖(FBG)、胰岛素敏感指数(HOMA-ISI)、CRP水平及血脂水平差异。结果治疗后第4、8周观察组患者血清FBG、CRP水平显著低于对照组,HOMA-ISI则显著高于对照组;观察组总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白(LDL-C)水平显著低于对照组(P<0.05)。结论吡格列酮能改善糖尿病胰岛素抵抗患者的血脂紊乱,降低血糖和CRP水平,增加胰岛素敏感性。
Objective To analyze the effect of pioglitazone on blood glucose, insulin sensitivity index and C-reactive protein (CRP) level in diabetic patients with insulin resistance and to explore its clinical efficacy in treating type 2 diabetes mellitus. Methods 180 cases of diabetic insulin resistance were randomly divided into control group and observation group, 90 cases in each group, the control group insulin treatment, the observation group patients were treated with pioglitazone combined with insulin, the fasting blood glucose (FBG) Insulin sensitivity index (HOMA-ISI), CRP levels and blood lipid levels. Results At the 4th and 8th week after treatment, the levels of serum FBG and CRP in the observation group were significantly lower than those in the control group and HOMA-ISI was significantly higher than that in the control group. The levels of total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL-C) levels were significantly lower than the control group (P <0.05). Conclusion Pioglitazone can improve the dyslipidemia, reduce the level of blood glucose and CRP, and increase the insulin sensitivity in diabetic insulin resistance patients.